PP
RIGL icon

Paloma Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Paloma Partners’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,352
Closed -$56K – 2132
2020
Q3 		$56K Buy
+2,352
New +$57.7K ﹤0.01% 1965
2020
Q1 		– Sell
-1,133
Closed -$24K – 1938
2019
Q4 		$24K Sell
1,133
-2,077
-65% -$42.8K ﹤0.01% 2097
2019
Q3 		$60K Buy
+3,210
New +$66.3K ﹤0.01% 1869
2015
Q2 		– Sell
-1,934
Closed -$69K – 1921
2015
Q1 		$69K Sell
1,934
-3,964
-67% -$109K ﹤0.01% 1140
2014
Q4 		$134K Buy
5,898
+1,350
+30% +$27.3K 0.01% 1050
2014
Q3 		$88K Buy
+4,548
New +$128K ﹤0.01% 908
2014
Q1 		– Sell
-4,576
Closed -$130K – 950
2013
Q4 		$130K Sell
4,576
-1,916
-30% -$56.2K 0.01% 939
2013
Q3 		$232K Buy
+6,492
New +$237K 0.01% 725

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Paloma Partners's RIGL Position: Q4 2020 in Review

Paloma Partners sold out of Rigel Pharmaceuticals (RIGL) in Q4 2020, closing a stake of 2,352 shares — an estimated $56K sold.

Paloma Partners first reported a position in RIGL in Q3 2013 and held it in 8 quarters. The position peaked at $232K in Q3 2013. 149 funds tracked by Wall St. Rank hold RIGL as of Q4 2020.

  • Paloma Partners reported no remaining Rigel Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Paloma Partners sold 2,352 Rigel Pharmaceuticals shares in Q4 2020, an estimated $56K.
  • Paloma Partners first reported a position in Rigel Pharmaceuticals in Q3 2013 and held it in 8 quarters.
  • Paloma Partners's Rigel Pharmaceuticals position peaked at $232K in Q3 2013.
  • 149 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2020.

Based on Paloma Partners's 13F filing for Q4 2020, filed 16 Feb 2021.